Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:09 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1245
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1189–1200 of 1,245 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2Phase 3 Interventional

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

NCT06450886
Site status not listed — check the official record
View directory record Official record
Conditions
Inclusion Body Myositis (IBM)
Interventions
Ulviprubart (ABC008)
Drug
Lead sponsor
Abcuro, Inc.
Industry
Eligibility
40 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Active, not recruiting Phase 2 Interventional

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

NCT03670056
Site status not listed — check the official record
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Combination immunotherapy with Ipilimumab and Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening

NCT06120205
Site status not listed — check the official record
View directory record Official record
Conditions
Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
Interventions
Teal Wand Self-Collection Device Group
Device
Lead sponsor
Teal Health, Inc.
Industry
Eligibility
25 Years to 65 Years · Female only
Enrollment
870 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Recruiting Not applicable Interventional

Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use

NCT06171412
Status at this site: Recruiting
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Glu-COACH
Behavioral
Lead sponsor
Yale University
Other
Eligibility
13 Years to 21 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Active, not recruiting No phase listed Observational

A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

NCT02130362
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn's Disease
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

TrialNet Pathway to Prevention of T1D

NCT00097292
Status at this site: Recruiting
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 45 Years
Enrollment
75,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2030
U.S. locations
17
States / cities
Orange, California • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Recruiting Phase 2 Interventional

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615
Status at this site: Recruiting
View directory record Official record
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Recruiting Phase 1 Interventional

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT05785754
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
DCSZ11, Pembrolizumab, Doxorubicin, Tebentafusp
Drug
Lead sponsor
DynamiCure Biotechnology
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Active, not recruiting Not applicable Interventional

Post-Approval Study of the TREO Abdominal Stent-Graft System

NCT04697784
Site status not listed — check the official record
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
TREO Abdominal Stent-Graft System
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246
Site status not listed — check the official record
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
Interventions
Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
64
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Active, not recruiting Not applicable Interventional

US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus

NCT05232838
Site status not listed — check the official record
View directory record Official record
Conditions
Hydrocephalus, Normal Pressure, Hydrocephalus
Interventions
eShunt Implant
Device
Lead sponsor
CereVasc Inc
Industry
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Jacksonville, Florida • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Nov 3, 2026, 5:09 PM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

Systems Investigation of Vaccine Responses in Aging and Frailty

NCT05291676
Status at this site: Recruiting
View directory record Official record
Conditions
Influenza
Interventions
Fluzone, Fluad
Biological
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Nov 3, 2026, 5:09 PM EST

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.